-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Pathology
-
The New WHO Classification of Lung Tumors
Ming S. Tsao, MD, FRCPC, of the Princess Margaret Cancer Centre, Toronto, delivered a Plenary Presentation during the 2020 World Conference on Lung Cancer outlining key updates found in the 5th edition of the World Health Organization (WHO) Book on Classification of Thoracic Tumours. The new book has implemented many new formats and involve new…
-
Lung Cancer Biomarker Testing Patterns Varied Widely in Japan
A significant number of patients with lung cancer did not undergo testing for all relevant biomarkers, according to real-world data from a study in Japan (MA08.08), and use of simultaneous testing compared with sequential testing may affect time to treatment. Yasushi Yatabe, MD, PhD, of the department of diagnostic pathology, National Cancer Center Hospital, Tokyo,…